• SEC Filings

FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Other Events
Item 8.01

On July 22, 2019, FibroGen, Inc. (“FibroGen”) issued a press release announcing dosing of the first patient in ZEPHYRUS, FibroGen’s Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

FIBROGEN INC Exhibit
EX-99.1 2 fgen-ex991_6.htm EX-99.1 fgen-ex991_6.htm Exhibit 99.1       FibroGen Announces First Patient Dosed in ZEPHYRUS,…
To view the full exhibit click here

About FibroGen, Inc. (NASDAQ:FGEN)

FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.